These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33876843)

  • 1. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
    Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
    J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
    Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
    J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
    Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
    Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
    Liu F; Zhang H; Song H
    Oncol Rep; 2017 Jan; 37(1):83-90. PubMed ID: 27878304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer.
    Bhatt AB; Wright TD; Barnes V; Chakrabarty S; Matossian MD; Lexner E; Ucar DA; Miele L; Flaherty PT; Burow ME; Cavanaugh JE
    Transl Oncol; 2021 Jun; 14(6):101046. PubMed ID: 33761370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.
    Pavan S; Meyer-Schaller N; Diepenbruck M; Kalathur RKR; Saxena M; Christofori G
    Oncogene; 2018 Aug; 37(31):4197-4213. PubMed ID: 29713055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
    Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
    PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
    Qin H; Liu X; Li F; Miao L; Li T; Xu B; An X; Muth A; Thompson PR; Coonrod SA; Zhang X
    Cancer Lett; 2017 Nov; 409():30-41. PubMed ID: 28844713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer.
    Matossian MD; Hoang VT; Burks HE; La J; Elliott S; Brock C; Rusch DB; Buechlein A; Nephew KP; Bhatt A; Cavanaugh JE; Flaherty PT; Collins-Burow BM; Burow ME
    Oncoscience; 2021; 8():64-71. PubMed ID: 34026925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Fang D; Chen H; Zhu JY; Wang W; Teng Y; Ding HF; Jing Q; Su SB; Huang S
    Oncogene; 2017 Mar; 36(11):1546-1558. PubMed ID: 27617576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK5/ERK5 pathway: the first fifteen years.
    Drew BA; Burow ME; Beckman BS
    Biochim Biophys Acta; 2012 Jan; 1825(1):37-48. PubMed ID: 22020294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation.
    Raviv Z; Kalie E; Seger R
    J Cell Sci; 2004 Apr; 117(Pt 9):1773-84. PubMed ID: 15075238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
    Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
    Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
    Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
    Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
    Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
    Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.